| Literature DB >> 35631379 |
Bruno Bueno-Silva1,2, Manuela Rocha Bueno1, Dione Kawamoto1, Renato C Casarin3, João Marcos Spessoto Pingueiro2, Severino Matias Alencar4, Pedro Luiz Rosalen3, Marcia Pinto Alves Mayer1.
Abstract
The isoflavone (3S)-vestitol, obtained from red propolis, has exhibited anti-inflammatory, antimicrobial, and anti-caries activity; however, few manuscripts deal with its anti-inflammatory mechanisms in macrophages. The objective is to elucidate the anti-inflammatory mechanisms of (3S)-vestitol on those cells. Peritoneal macrophages of C57BL6 mice, stimulated with lipopolysaccharide, were treated with 0.37 to 0.59 µM of (3S)-vestitol for 48 h. Then, nitric oxide (NO) quantities, macrophages viability, the release of 20 cytokines and the transcription of several genes related to cytokine production and inflammatory response were evaluated. The Tukey-Kramer variance analysis test statistically analyzed the data. (3S)-vestitol 0.55 µM (V55) lowered NO release by 60% without altering cell viability and diminished IL-1β, IL-1α, G-CSF, IL-10 and GM-CSF levels. V55 reduced expression of Icam-1, Wnt5a and Mmp7 (associated to inflammation and tissue destruction in periodontitis) and Scd1, Scd2, Egf1 (correlated to atherosclerosis). V55 increased expression of Socs3 and Dab2 genes (inhibitors of cytokine signaling and NF-κB pathway), Apoe (associated to atherosclerosis control), Igf1 (encoder a protein with analogous effects to insulin) and Fgf10 (fibroblasts growth factor). (3S)-vestitol anti-inflammatory mechanisms involve cytokines and NF-κB pathway inhibition. Moreover, (3S)-vestitol may be a candidate for future in vivo investigations about the treatment/prevention of persistent inflammatory diseases such as atherosclerosis and periodontitis.Entities:
Keywords: inflammation; natural products; propolis
Year: 2022 PMID: 35631379 PMCID: PMC9145271 DOI: 10.3390/ph15050553
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1(3S)-vestitol effects on NO release and macrophage viability of LPS-stimulated peritoneal cells (n = 6). * statistical difference compared to control group by one-way ANOVA plus Tukey post-hoc test, p <0.05).
Figure 2Cytokines profile of LPS-activated peritoneal macrophages treated with (3S)-Vestitol 0.55 µM (n = 6). * statistical difference compared to vehicle-control group (Mann-Whitney, p <0.05).
Figure 3Gene expression analysis of LPS-activated peritoneal macrophage treated with (3S)-vestitol 0.55 µM. Statistical Analysis: Student’s t-test was conducted to assess statistical significance between vehicle-control and V55 group utilizing mean CT values obtained from the triplicate samples (p < 0.05). * statistical difference compared to control group by statistical analysis-SABiosciences Technical Core (SABiosciences/Qiagen Corp., Frederick, MD, USA).
Figure 4Molecular mechanisms of (3S)-vestitol anti-inflammatory actions in LPS stimulated peritoneal macrophages. “Red down arrow” indicates the decrease of genes transcription and/or pathway activation by (3S)-vestitol treatment while an “blue up arrow” indicated the up-regulation of gene expression and/or pathway activation due to (3S)-vestitol treatment. Adapted from Qiagen’s website [31].
Figure 5Chemical structure of (3S)-vestitol, isolated from Brazilian red propolis. (Figure obtained from [46]).